AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients. AbbVie will price its two-pill drug like its Viekira Pak, another hepatitis C combination that goes for about $28,000 per month. AbbVie will aggressively market the two-drug combo against Gilead's Harvoni and Epclusa, he said. This strategy is likely to result in significant market share for AbbVie, given the convenience and excellent efficacy of their two-drug combination
I hope the Karma bitch bites everyone here hard, especially KD in the northeast....total douche. Everyone else with a hair across their ass that we were the only game in town deserves whatever comes along. Pompous shit heads